Clinical and MRI response to dose reduction of an etanercept-biosimilar for hip arthritis in patients with ankylosing spondylitis: an observational, retrospective cohort study.
Zhi-Xiang HuangWei-Ming DengXin GuoZheng-Ping HuangYu-Kai HuangChu-Lan LinTian-Wang LiPublished in: Clinical rheumatology (2019)
Efficacy of Yisaipu® tapering treatment is comparable to the full-dose therapy for hip arthritis in AS patients. Both treatments maintain remission of hip arthritis after patients achieved low disease activity.
Keyphrases
- rheumatoid arthritis
- disease activity
- ankylosing spondylitis
- end stage renal disease
- systemic lupus erythematosus
- ejection fraction
- newly diagnosed
- chronic kidney disease
- rheumatoid arthritis patients
- prognostic factors
- juvenile idiopathic arthritis
- magnetic resonance imaging
- magnetic resonance
- cross sectional
- diffusion weighted imaging
- replacement therapy